drugset
drugset / Trial / NCT05194839

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

NCT05194839 ↗

Phase 2 Terminated 79 enrolled Aristea Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A 12-week Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis followed by an Open-label Extension Phase.

Timeline

Start
2022-01-05
Primary completion
2023-02-13
Completion
2023-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject VIMNERIXIN Small molecule 200 mg —
Subject VIMNERIXIN Small molecule 400 mg —

Indications

palmoplantar pustulosis